to accelerate the development of innovative prophylactic and therapeutic treatments in the field of respiratory infections
Marcy l’Etoile, Lyon, France – June 13th, 2022
The Covid-19 crisis has highlighted the need to pool and leverage scientific and technical expertise in order to be more reactive to the (re)-emergence of infectious diseases. On the basis of a public-private partnership initiated in 2017, Cynbiose and VirNext teams collaborate closely on various aspects of Research and Development in the field of respiratory infectious diseases. The two organizations based in the Auvergne-Rhone-Alpes region, the historical birthplace of vaccines and diagnostics, have already developed several in vitro and in vivo models of infections by respiratory viruses such as influenza, pneumovirus (hRSV, hMPV) and coronavirus (SARS-CoV-2).